Cliff ERS - Search Results

1

Use of subjective minimizing language at hematology and oncology conferences: A systematic review.

Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. Abusamak AA, et al. Among authors: cliff ers. J Cancer Policy. 2024 Mar;39:100461. doi: 10.1016/j.jcpo.2023.100461. Epub 2023 Dec 5. J Cancer Policy. 2024. PMID: 38061494

2

Overall survival as a primary end point in multiple myeloma trials.

Cliff ERS, Mohyuddin GR. Cliff ERS, et al. Nat Rev Clin Oncol. 2022 Sep;19(9):565-566. doi: 10.1038/s41571-022-00665-7. Nat Rev Clin Oncol. 2022. PMID: 35821523 No abstract available.

3

Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease-Estimating the True Value.

Cliff ERS, Kelkar AH. Cliff ERS, et al. JAMA Neurol. 2022 Oct 3. doi: 10.1001/jamaneurol.2022.3101. Online ahead of print. JAMA Neurol. 2022. PMID: 36190718 No abstract available.

4

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Cliff ERS, Mian H, Mohyuddin GR. Cliff ERS, et al. N Engl J Med. 2022 Nov 3;387(18):1721-1722. doi: 10.1056/NEJMc2211969. N Engl J Med. 2022. PMID: 36322860 No abstract available.

5

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.

Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. Van Oekelen O, et al. Among authors: cliff ers. Blood Cancer J. 2022 Nov 15;12(11):155. doi: 10.1038/s41408-022-00750-1. Blood Cancer J. 2022. PMID: 36379917 Free PMC article. Review. No abstract available.

6

The promise and harms of screening for plasma cell dyscrasias.

Mohyuddin GR, Chakraborty R, Cliff ERS. Mohyuddin GR, et al. Among authors: cliff ers. Br J Haematol. 2023 Mar;200(6):704-707. doi: 10.1111/bjh.18634. Epub 2023 Jan 10. Br J Haematol. 2023. PMID: 36626939 Review.

7

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.

Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Cliff ERS, et al. J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716411 No abstract available.

8

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions.

Cliff ERS, Kelkar AH, Russler-Germain DA, Tessema FA, Raymakers AJN, Feldman WB, Kesselheim AS. Cliff ERS, et al. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e397912. doi: 10.1200/EDBK_397912. Am Soc Clin Oncol Educ Book. 2023. PMID: 37433102 Free article. Review.

9

All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results.

Kelkar AH, Shimony S, Cliff ERS, Stone RM. Kelkar AH, et al. Among authors: cliff ers. Lancet Haematol. 2023 Sep;10(9):e706-e707. doi: 10.1016/S2352-3026(23)00237-5. Lancet Haematol. 2023. PMID: 37652597 No abstract available.

10

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma.

Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Najjar M, et al. Among authors: cliff ers. JAMA Netw Open. 2023 Nov 1;6(11):e2342195. doi: 10.1001/jamanetworkopen.2023.42195. JAMA Netw Open. 2023. PMID: 37948080 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page